Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Hara, Yuka ^a   Mohamed, Rahmah ^a   Nathan, Sheila ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; RECOMBINANT OUTER MEMBRANE PROTEIN 3; RECOMBINANT OUTER MEMBRANE PROTEIN 7; RECOMBINANT OUTER MEMBRANE PROTEIN A; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BURKHOLDERIA PSEUDOMALLEI; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE SEQUENCE; HUMAN; IMMUNOGENICITY; MELIOIDOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PILOT STUDY; PROTEIN DOMAIN; PROTEIN TARGETING; VACCINE PRODUCTION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

ANIMALIA; BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BLOTTING, WESTERN; BURKHOLDERIA PSEUDOMALLEI; GENOME, BACTERIAL; HUMANS; MELIOIDOSIS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PILOT PROJECTS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 68349144381     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006496     Document Type: Article

References (38)

1. Dance DA (2002) Melioidosis. Curr Opin Infect 96: 72-76.
2. Leelarasamee A (2004) Recent development in melioidosis. Curr Opin Infect Dis 17: 131-136.
3. Cheng AC, Currie BJ (2005) Melioidosis: Epidemiology, pathophysiology and management. Clin Microbiol Rev 18: 383-416.
4. Haque A, Chu K, Easton A, Stevens MP, Galyov EE, et al. (2006) A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis 194: 1241-1248.
5. Lertpatanasuwan N, Sermsri K, Petkaseam A, Trakulsomboon S, Thamlikitkul V, et al. (1999) Arabinose-positive Burkholderia pseudomallei infection in humans: case report. Clin Infect Dis 28: 927-928.
6. Healey GD, Elvin SJ,MortonM,Williamson ED (2005) Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance post-infection. Infect Immun 73: 5945-5951.
7. Brett PJ, Woods DE (1996) Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun 64: 2824-2828.
8. Nelson M, Prior JL, Lever S, Jones HE, Atkins TP, et al. (2004) Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 53: 1177-1182.
9. Chen YS, Hsiao YS, Lin HH, Yen CM, Chen AC, et al. (2005) Immunogenicity and anti-Burkholderia pseudomallei activity in BALB/c mice immunized with plasmid DNA encoding flagellin. Vaccine 24: 750-758.
10. Das M, Chopra AK, Cantu JM, Peterson JW (1998) Antisera to selected outer membrane proteins of Vibrio cholerae protect against challenge with homologous and heterologous strains of V. cholerae. FEMS Immunol Med Microbiol 22: 303-308.
11. Weiser JN, Gotschlich EC (1991) Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect Immun 59: 2252-2258.
12. Ross BC, Czajkowski L, Vandenberg KL, Camuglia S, Woods J, et al. (2004) Characterization of two outer membrane protein antigens of Porphyromonas gingivalis that are protective in a murine lesion model. Oral Microbiol Immunol 19: 6-15.
13. Ulett GC, Currie BJ, Clair TW, Mayo M, Ketheesan N, et al. (2001) Burkholdeira pseudomallei virulence: definition, stability and association with clonality. Microbes Infect 3: 621-631.
14. Ulett GC, Labrooy JT, Currie BJ, Barnes JL, Ketheesan N (2005) A model of immunity for Burkholderia pseudomallei unique responses following immunization and acute lethal infection. Microbes Infect 7: 1263-1275.
15. Stevens MP, Stevens JM, Jeng RL, Taylor LA, Wood MW, et al. (2005) Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol Microbiol 56: 40-53.
16. Subramaniam S, Huang B, Loh H, Kwang J, Tan HM, et al. (2000) Characterization of a predominant immunogenic outer membrane protein of Riemerella anatipestifer. Clin Diagn Lab Immunol 7: 168-174.
17. Grizot S, Buchanan SK (2004) Structure of the OmpA-like domain of RmpM from Neisseria meningitidis. Mol Microbiol 51: 1027-1037.
18. Kim SK, Devine L, Angevine M, DeMars R, Kavathas PB (2000) Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers. J Immunol 165: 7285-7292.
19. Jeannin P, Magistrelli G, Goetsch L, Haeuw J-F, Thieblemont N, et al. (2002) Outer membrane protein A (OmpA): a new pathogen associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies. Vaccine 20: A23-A27.
20. Poolman JT (1996) Bacterial outer membrane protein vaccines: The meningococcal example. Adv Exp Med 397: 73-77.
21. Wang Y (2002) The function of OmpA in Escherichia coli. Biochem and Biophys Res Commun 292: 396-401.
22. Puohiniemi R, Karvonen M, Vuopio-Varkila J, Muotiala A, Helander IM, et al. (1990) A strong antibody response to the periplasmic C-terminal domain of the OmpA protein of Escherichia coli is produced by immunization with purified OmpA or with whole E. coli or Salmonella typhimurium bacteria. Infect Immun 58: 1691-1696.
23. Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ (1999) Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 67: 3593-3600.
24. Snapper CM, Paul WE (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
25. Chen YL, Wang SN, Yang WJ, Chen YJ, Lin HH, et al. (2003) Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination. Infect Immun 71: 1155-1160.
26. Jones L, Beveridge TJ, Woods DE (1996) Intracellular survival of Burkholderia pseudomallei. Infect Immun 64: 782-790.
27. Chaowagul W, Suputtamongkol Y, Dance DA, Rajchanuvong A, Pattaraarechachai J, et al. (1993) Relapse in melioidosis: incidence and risk factors. J Infect Dis 168: 1181-1185.
28. Elvin SJ, Healey GD, Westwood A, Knight SC, Eyles JE, et al. (2006) Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun 74: 1706-1711.
29. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403-10.
30. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, et al. (2000) Artemis: sequence visualisation and annotation. Bioinformatics 16: 944-945.
31. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) ClustalW and ClustalX version 2. Bioinformatics 23: 2947-2948.
32. Clamp M, Cuff J, Searle SM, Barton GJ (2004) The Jalview Java alignment editor. Bioinformatics 20: 426-427.
33. Lee SH, Chong CE, Lim BS, Chai SJ, Sam KK, et al. (2007) Burkholderia pseudomallei animal and human isolates from Malaysia exhibit different phenotypic characteristics. Diag Microbiol Infect Dis 58: 263-270.
34. Sambrook J, Russell DW (2001) Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor, Cold Spring Harbor Laboratory, New York.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, et al. (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
36. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
37. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354.
38. Chin CY, Othman R, Nathan S (2007) The Burkholderia pseudomallei serine protease MprA is auto-proteolytically activated to produce a highly stable enzyme. Enzyme Microbiol Technol 40: 370-377.